ERISA Ledger · U.S. DOL EBSA Form 5500 (2024)

Karyopharm Therapeutics INC.

Official 2024 U.S. DOL Form 5500 summary for Karyopharm Therapeutics INC. (Karyopharm Therapeutics INC. 401(k) Plan · EIN 26-3931704 · PN 001): $55.63M net assets, 284 active participants, and $12.37 per $10,000 (12.37 bps).

Reported Form 5500 Fee & Service Summary

Plan SponsorKaryopharm Therapeutics INC.
Filing IdentifierKaryopharm Therapeutics INC. 401(k) Plan · EIN 26-3931704 · PN 001
Plan Category & State401(k) Defined Contribution (MA)
Asset-Size Peer Cohort$25M-$100M
Plan Net Assets (2024)$55.63M
Active Participants284
Direct Admin Fee Rate$12.37 per $10,000 (12.37 bps)
Cohort Peer Median$19.23 per $10,000 (19.23 bps)
Primary Recordkeeper / ProviderFidelity Investments
Schedule H Line 4a RemittanceSchedule H Line 4a Late Remittance Reported ($152.00, often administrative timing)

Browse all 78,373 plans & Schedule C vendors · Methodology · Meru AI